• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Quantum-Si Reports Fourth Quarter and Full Year 2023 Financial Results

    2/29/24 4:05:00 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials
    Get the next $QSI alert in real time by email

    Finalizing Commercial Readiness for Expected Full Commercial Launch by the End of Q1 2024

    Releases Full Year 2024 Financial Guidance

    Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced financial results for the fourth quarter and full year ended December 31, 2023.

    Press Release Highlights

    • Recorded revenue of $400,000 in the fourth quarter of 2023 as the Company continued its previously communicated controlled commercial launch of its Platinum® instrument
    • Finalizing commercial readiness for expected full commercial launch by the end of Q1 2024
    • Launched version 2 of its sequencing kit in early February 2024 and has begun shipping to customers
    • Announced the Company's third international distribution partner, TOMY Digital Biology Co. Ltd., based in Japan
    • Announced the planned release of a version 3 of its sequencing kit by the end of Q3 2024
    • Provides full year 2024 financial guidance

    "We made great progress in the fourth quarter of 2023 and are seeing the early results of that work now, including the launch of our version 2 sequencing kit in early February 2024, significant progress on scaling up our commercial resources, and the addition of our third distributor to our international network", said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. "We are pleased with our ability to launch the version 2 sequencing kit well within the previously provided timeline. We are excited about the acceleration we are seeing in our R&D pipeline and believe we are in a strong position to deliver a steady cadence of product enhancements and new capabilities to the market in 2024 and beyond. A version 3 of our sequencing kit is under development now and we expect to deliver it to the market by the end of Q3 2024. We are also making solid progress across library prep and instrument development programs that we believe will fuel the future growth of the Company for years to come."

    Hawkins continued, "With all the progress that we have made over the last year, coupled with finalizing our commercialization readiness, I am pleased to announce that we expect to commence our full commercial launch of our Platinum® instrument by the end of Q1 2024. We have also released full year 2024 financial guidance."

    Fourth Quarter 2023 and Full Year 2023 Financial Results

    During the fourth quarter of 2023, the Company continued its controlled commercial launch of its Platinum instrument, recording revenue of $400,000. Gross profit was $178,000 and gross margin was 45%. For the full year ended December 31, 2023, the Company recorded revenue of $1.1 million, gross profit of $488,000, and gross margin of 45%. The periodic gross margin rate is expected to be variable in the near term as the Company works through the initial stages of commercialization as well as the timing and mix of product sales between instruments and consumable kits.

    Total operating expenses were $28.1 million in the fourth quarter of 2023, compared to $38.8 million for the same period in the prior year, and $111.7 million for the full year ended December 31, 2023, compared to $123.8 million for the same period in the prior year. Adjusted total operating expenses were $26.3 million in the fourth quarter of 2023, compared to $25.3 million for the same period in the prior year, and adjusted total operating expenses for the full year ended December 31, 2023, were $98.9 million compared to $103.2 million for the same period in the prior year. Overall adjusted operating expenses for 2023 compared to 2022 have decreased as the Company focused on deploying capital in an efficient manner to R&D projects while still building commercial capabilities.

    Net loss was $22.0 million in the fourth quarter of 2023, compared to a net loss of $33.1 million in the same period of the prior year, and a net loss of $96.0 million for the full year ended December 31, 2023, compared to a net loss of $132.4 million for the same period in the prior year. Adjusted EBITDA was negative $25.1 million in the fourth quarter of 2023, compared to negative $24.5 million in the same period of the prior year, and negative $94.3 million for the full year ended December 31, 2023, compared to negative $100.6 million for the same period in the prior year. A reconciliation of the non-GAAP financial measures, adjusted total operating expenses and adjusted EBITDA, is provided in a table included in this press release.

    As of December 31, 2023, the Company's cash and cash equivalents and investments in marketable securities were $257.7 million.

    2024 Financial Guidance

    For the full year 2024, the Company provided the following financial guidance:

    Revenue $3.7 - $4.2 million
    Adjusted total operating expenses Less than $103 million
    Total cash usage Less than $100 million

    The Company also maintains the expectation that the balance in cash and cash equivalents and investments in marketable securities of $257.7 million as of December 31, 2023 will provide a runway into 2026.

    Webcast and Conference Call Information

    Quantum-Si will host a conference call to discuss its fourth quarter and full year 2023 financial results on Thursday, February 29, 2024, at 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by joining the live webcast in the Investors section of the Quantum-Si website under Events & Presentations. Alternatively, individuals can register online to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event will be available for replay following the event.

    About Quantum-Si Incorporated

    Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X.

    Use of Non-GAAP Financial Measures

    This press release presents the non-GAAP financial measures "adjusted total operating expenses" and "adjusted EBITDA." The most directly comparable measures for these non-GAAP financial measures are total operating expenses and net loss. The Company has included below adjusted total operating expenses, which presents the Company's total operating expenses after excluding goodwill impairment, stock-based compensation and restructuring costs. In addition, adjusted EBITDA further excludes interest, taxes, depreciation, amortization, dividend income, unrealized and realized gains and losses on marketable securities, changes in fair value of warrant liabilities and other income or expense.

    A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding the Company's financial condition and results of operations is included as Exhibit 99.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on February 29, 2024.

    Forward Looking Statements

    This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company's ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company's existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company's commercialized Platinum™ protein sequencing instrument and kits and the Company's other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

    QUANTUM-SI INCORPORATED

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (in thousands, except per share amounts)

    (Unaudited)

     

    Three months ended December 31,

    Years ended December 31,

    2023

    2022

    2023

    2022

    Revenue
    Product

    $

    377

    $

    -

    $

    1,031

    $

    -

    Service

    23

    -

    51

    -

    Total revenue

    400

    -

    1,082

    -

     
    Cost of revenue

    222

    -

    594

    -

     
    Gross profit

    178

    -

    488

    -

    Operating expenses:
    Research and development

    16,437

    18,157

    67,025

    72,062

    Selling, general and administrative

    11,624

    11,203

    44,634

    42,296

    Goodwill impairment

    -

    9,483

    -

    9,483

    Total operating expenses

    28,061

    38,843

    111,659

    123,841

    Loss from operations

    (27,883)

    (38,843)

    (111,171)

    (123,841)

    Dividend income

    2,262

    2,013

    9,536

    5,301

    Gain (loss) on marketable securities, net

    3,774

    2,180

    5,587

    (20,603)

    Change in fair value of warrant liabilities

    (197)

    1,122

    (278)

    6,243

    Other (expense) income, net

    (4)

    388

    366

    458

    Loss before provision for income taxes

    (22,048)

    (33,140)

    (95,960)

    (132,442)

    Provision for income taxes

    -

    -

    -

    -

    Net loss and comprehensive loss

    $

    (22,048)

    $

    (33,140)

    $

    (95,960)

    $

    (132,442)

     
    Net loss per common share attributable to common stockholders, basic and diluted

    $

    (0.16)

    $

    (0.24)

    $

    (0.68)

    $

    (0.95)

    Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted

    141,575

    139,849

    141,300

    139,255

     

    QUANTUM-SI INCORPORATED

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands, except share and par value amounts)

    (Unaudited)

     

    December 31,

    December 31,

    2023

    2022

    Assets
    Current assets:
    Cash and cash equivalents

    $

    133,860

     

    $

    84,319

     

    Marketable securities

     

    123,876

     

     

    266,990

     

    Accounts receivable, net of allowance of $0 and $0, respectively

     

    368

     

     

    -

     

    Inventory, net

     

    3,945

     

     

    -

     

    Prepaid expenses and other current assets

     

    4,261

     

     

    6,873

     

    Total current assets

     

    266,310

     

     

    358,182

     

    Property and equipment, net

     

    16,275

     

     

    16,849

     

    Internally developed software

     

    532

     

     

    -

     

    Operating lease right-of-use assets

     

    14,438

     

     

    15,757

     

    Other assets

     

    695

     

     

    697

     

    Total assets

    $

    298,250

     

    $

    391,485

     

    Liabilities and stockholders' equity
    Current liabilities:
    Accounts payable

    $

    1,766

     

    $

    3,903

     

    Accrued expenses and other current liabilities

     

    8,277

     

     

    10,434

     

    Current portion of operating lease liabilities

     

    1,566

     

     

    1,369

     

    Total current liabilities

     

    11,609

     

     

    15,706

     

    Warrant liabilities

     

    1,274

     

     

    996

     

    Operating lease liabilities

     

    13,737

     

     

    16,077

     

    Other long-term liabilities

     

    11

     

     

    -

     

    Total liabilities

     

    26,631

     

     

    32,779

     

     
    Stockholders' equity
    Class A Common stock, $0.0001 par value; 600,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 121,832,417 and 120,006,757 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.

     

    12

     

     

    12

     

    Class B Common stock, $0.0001 par value; 27,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 19,937,500 shares issued and outstanding as of December 31, 2023 and December 31, 2022.

     

    2

     

     

    2

     

    Additional paid-in capital

     

    767,239

     

     

    758,366

     

    Accumulated deficit

     

    (495,634

    )

     

    (399,674

    )

    Total stockholders' equity

     

    271,619

     

     

    358,706

     

    Total liabilities and stockholders' equity

    $

    298,250

     

    $

    391,485

     

     

    QUANTUM-SI INCORPORATED

    RECONCILIATION OF U.S. GAAP TO NON-GAAP FINANCIAL MEASURES

    (in thousands)

    (Unaudited)

     

    Three months ended December 31,

    Years ended December 31,

    2023

    2022

    2023

    2022

    Net loss

    $

    (22,048

    )

    $

    (33,140

    )

    $

    (95,960

    )

    $

    (132,442

    )

    Adjustments to reconcile to EBITDA:
    Dividend income

     

    (2,262

    )

     

    (2,013

    )

     

    (9,536

    )

     

    (5,301

    )

    Depreciation and amortization

     

    1,093

     

     

    795

     

     

    4,156

     

     

    2,584

     

    EBITDA

     

    (23,217

    )

     

    (34,358

    )

     

    (101,340

    )

     

    (135,159

    )

    Adjustments to reconcile to Adjusted EBITDA:
    Goodwill impairment

     

    -

     

     

    9,483

     

     

    -

     

     

    9,483

     

    (Gain) loss on marketable securities, net

     

    (3,774

    )

     

    (2,180

    )

     

    (5,587

    )

     

    20,603

     

    Change in fair value of warrant liabilities

     

    197

     

     

    (1,122

    )

     

    278

     

     

    (6,243

    )

    Other expense (income), net

     

    4

     

     

    (388

    )

     

    (366

    )

     

    (458

    )

    Stock-based compensation

     

    1,339

     

     

    4,107

     

     

    8,253

     

     

    11,206

     

    Restructuring costs

     

    373

     

     

    -

     

     

    4,504

     

     

    -

     

    Adjusted EBITDA

    $

    (25,078

    )

    $

    (24,458

    )

    $

    (94,258

    )

    $

    (100,568

    )

     
     
     

    Three months ended December 31,

    Years ended December 31,

    2023

    2022

    2023

    2022

    Total operating expenses

    $

    28,061

     

    $

    38,843

     

    $

    111,659

     

    $

    123,841

     

    Adjustments to reconcile to Adjusted total operating expenses:
    Stock-based compensation

     

    (1,339

    )

     

    (4,107

    )

     

    (8,253

    )

     

    (11,206

    )

    Restructuring costs

     

    (373

    )

     

    -

     

     

    (4,504

    )

     

    -

     

    Goodwill impairment

     

    -

     

     

    (9,483

    )

     

    -

     

     

    (9,483

    )

    Adjusted total operating expenses

    $

    26,349

     

    $

    25,253

     

    $

    98,902

     

    $

    103,152

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240229043793/en/

    Get the next $QSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QSI

    DatePrice TargetRatingAnalyst
    2/7/2025$3.75Buy
    Alliance Global Partners
    12/8/2023$3.00Buy
    H.C. Wainwright
    9/25/2023$3.50 → $2.00Buy → Hold
    Canaccord Genuity
    10/20/2021$13.00Buy
    Canaccord Genuity
    More analyst ratings

    $QSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Quantum-Si Incorporated

      SC 13D/A - Quantum-Si Inc (0001816431) (Subject)

      9/17/24 4:24:56 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Quantum-Si Incorporated

      SC 13G/A - Quantum-Si Inc (0001816431) (Subject)

      6/28/24 5:16:32 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G filed by Quantum-Si Incorporated

      SC 13G - Quantum-Si Inc (0001816431) (Subject)

      2/13/24 9:41:18 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Hawkins Jeffrey Alan sold $32,846 worth of shares (23,707 units at $1.39), decreasing direct ownership by 0.89% to 2,646,716 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      3/24/25 6:48:37 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • General Counsel & Corp. Secr. Lapointe Christian sold $6,783 worth of shares (4,896 units at $1.39), decreasing direct ownership by 0.50% to 983,480 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      3/24/25 6:42:56 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Chief Financial Officer Keyes Jeffry R. sold $11,951 worth of shares (8,626 units at $1.39), decreasing direct ownership by 0.72% to 1,188,194 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      3/24/25 6:34:27 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    SEC Filings

    See more
    • Quantum-Si Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Quantum-Si Inc (0001816431) (Filer)

      4/10/25 4:49:41 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • SEC Form DEFA14A filed by Quantum-Si Incorporated

      DEFA14A - Quantum-Si Inc (0001816431) (Filer)

      3/20/25 4:12:20 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • SEC Form DEF 14A filed by Quantum-Si Incorporated

      DEF 14A - Quantum-Si Inc (0001816431) (Filer)

      3/20/25 4:07:34 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Financials

    Live finance-specific insights

    See more
    • Quantum-Si to Report First Quarter 2025 Financial Results on May 15, 2025

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the first quarter 2025 on Thursday, May 15, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personali

      4/24/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Reports Fourth Quarter and Full Year 2024 Financial Results

      Achieves First Quarterly Revenue Over $1 Million Completes Capital Raises of $86 Million Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the fourth quarter and full year ended December 31, 2024. Press Release Highlights Reported revenue of $1.2 million for the fourth quarter of 2024 and $3.1 million for the full year 2024 (representing a 183% full year-over-year growth) Raised capital of over $86 million between the fourth quarter of 2024 and first week of 2025 (extending cash runway into the second half of 2027) Announced the launch of Platinum® Pro in January 2025, with shipp

      3/3/25 4:05:00 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 3, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in numbe

      2/12/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quantum-Si to Report First Quarter 2025 Financial Results on May 15, 2025

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the first quarter 2025 on Thursday, May 15, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personali

      4/24/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Begins Shipping Platinum® Pro, Advancing Accessibility in Next-Gen Protein Sequencing™

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, announces the start of shipments for its latest benchtop sequencer, Platinum® Pro. This groundbreaking instrument offers protein analysis with single-molecule precision, aiming to make Next-Gen Protein Sequencing™ more accessible to laboratories worldwide. Platinum Pro delivers a comprehensive solution for sequencing and analyzing proteins through a simple, integrated workflow. Building upon the foundation of innovation established by the original Platinum, the new system introduces advanced features tailored to the evolving needs of researchers and biopharmaceutical customers. Key

      3/26/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si to Participate in DNAnexus Webinar on Large Scale Proteomics in Multi-Omics Research

      Validate multi-omics findings at the single-molecule level with Next-Gen Protein Sequencing™ Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, announces participation in an upcoming DNAnexus webinar focused on the role of proteomics in multi-omics research. This discussion will explore how the integration of proteomics data with other omics datasets is driving new discoveries in disease research, including cancer. When: March 25, 2025, at 8 a.m. PT/11 a.m. ET Attendees will learn about: The growing impact of proteomics in multi-omics analysis Applications for cancer and other disease research Technologies and strategies fo

      3/20/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Keyes Jeffry R. bought $43,465 worth of shares (50,000 units at $0.87), increasing direct ownership by 13% to 446,820 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      8/13/24 6:01:25 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • President & CEO Hawkins Jeffrey Alan bought $21,272 worth of shares (25,000 units at $0.85), increasing direct ownership by 3% to 1,003,757 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      8/13/24 6:01:28 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Director Kummeth Charles R. bought $148,459 worth of shares (170,000 units at $0.87), increasing direct ownership by 92% to 355,000 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      8/13/24 6:01:24 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on Quantum-Si with a new price target

      Alliance Global Partners initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.75

      2/7/25 8:29:38 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • H.C. Wainwright initiated coverage on Quantum-Si with a new price target

      H.C. Wainwright initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.00

      12/8/23 7:55:31 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Quantum-Si from Buy to Hold and set a new price target of $2.00 from $3.50 previously

      9/25/23 9:04:14 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Leadership Updates

    Live Leadership Updates

    See more
    • Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to serve as independent Chairman of the Board of Directors

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman of the Board, effective May 27, 2024. Mr. Kummeth has over 35 years of leadership experience in Life Sciences most recently as President and CEO of Bio-Techne. During Mr. Kummeth's tenure at Bio-Techne, he oversaw tremendous growth across all aspects of the business including annual revenue growth from $300M to over $1.1B, growth in the employee base from 800 to over 3,000, and the successful execution of 19 acquisitions, all while maintaining a 35% or better EBITDA level. Under Mr. Ku

      5/30/24 4:05:00 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Appoints Former Illumina and Cisco Systems Executive, Paula Dowdy, to its Board of Directors

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced the appointment of Paula Dowdy, a senior executive with more than 35 years of experience across life sciences, enterprise software, and technology industries, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321183506/en/Paula Dowdy (Photo: Business Wire) Ms. Dowdy currently serves on the Board of Directors for SPT Labtech, a world leading lab automation tools company based in the UK and is an advisor at EQT Life Sciences, one of Europe's leading investors targeting innovative

      3/21/24 4:05:00 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Introduces World's First Next-Generation Protein Sequencer™ in Japan with Addition of New Distributor

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it has entered into an agreement with a new distributor who will make the company's protein sequencing instrument, Platinum® available for the first time in Japan. TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si's next-generation protein sequencer™ and associated consumables throughout Japan. "Working with Quantum-Si marks a pivotal moment for TOMY Digital Biology, aligning with our commitment to advancing life sciences. We're poised to empower Japanese researchers wit

      1/18/24 8:30:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials